← All organizations
Highest phase reached
Phase 4
First clinical trial
Mar 1, 2001Last known activity
Jun 10, 2025
Acquired by Illumina, Inc. on Jan 1, 2011
Timeline
1980s
- Jan 1, 1986
Epicentre— Founded
2010s
- Jan 1, 2011
Illumina, Inc.— Acquired By
Drugs by trial phase (46 distinct, 31 trials)
Phase 4 (15 own, 0 via acquisition)
Phase 3 (23 own, 0 via acquisition)
Phase 2 (4 own, 0 via acquisition)
Other trials (4 own, 0 via acquisition)
Indications
Studied for
- Bacterial Infections
- Communicable Diseases
- Fever
- Gastroenteritis
- Gram-Positive Bacterial Infections
- Hemorrhagic Fever, Ebola
- Infections
- Leg Injuries
- Malaria
- Malaria, Cerebral
- Malaria, Falciparum
- Malnutrition
- Meningitis
- Meningitis, Meningococcal
- Meningococcal Infections
- Mycobacterium Infections
- Severe Acute Malnutrition
- Trypanosomiasis
- Trypanosomiasis, African
- Tuberculosis
- Tuberculosis, Multidrug-Resistant
- Tuberculosis, Pulmonary
- Virus Diseases
- Wounds and Injuries
- Yellow Fever
Recent trials (50)
- NCT06860178Lead sponsorPhase 4Jun 10, 2025
- NCT05909358CollaboratorPhase 1/Phase 2Jul 31, 2023
- NCT05453253Lead sponsorPhase 4Jul 20, 2022
- NCT05175014Lead sponsorPhase 4Dec 30, 2021
- NCT04409483Study directorPhase 3Jun 1, 2020
- NCT04409483Lead sponsorPhase 3Jun 1, 2020
- NCT04390594CollaboratorPhase 3Jun 1, 2020
- NCT04152486CollaboratorPhase 3Nov 14, 2019
- NCT04059471CollaboratorPhase 4Aug 12, 2019
- NCT03896685CollaboratorPhase 3Jun 30, 2019
- NCT03431675Lead sponsorPhase 4Feb 28, 2018
- NCT03431675Study directorPhase 4Feb 28, 2018
- NCT02991495Lead sponsorPhase 4Jul 30, 2017
- NCT03161366Lead sponsorPhase 3Jul 1, 2017
- NCT02724046Lead sponsorPhase 4Apr 22, 2017
Details
- Founded
- Paris, FR Jan 1, 1986
- Last known activity
- Jun 10, 2025